Recovery after PFA combines rest in the first hours with rhythm checks and medicines over the following months. A written discharge plan brings these steps together: wound and activity instructions, prescribed medicines, follow-up contacts and arrangements for the journey home.

PFA may limit injury to nearby tissues, but it is still an invasive catheter procedure. In MANIFEST-17K, major complications were reported in 173 of 17,642 patients—about one in a hundred. No reported injury in a particular category does not mean that its future risk is zero.

PFA is a treatment option for persistent AF as well as paroxysmal AF. In ADVANTAGE AF, which treated persistent AF with FARAPULSE, 85.3% were free from symptomatic AF at one year; the stricter primary effectiveness estimate was 63.5%. The study treated the pulmonary veins and posterior wall and had no thermal-ablation control group, so it does not show that PFA is better than thermal ablation.

PFA treats AF through a catheter, using electrical pulses rather than heating or freezing tissue. Its main AF target is pulmonary vein isolation. It remains an invasive procedure: the device, your AF pattern and the team’s plan matter as much as the energy source.

If paroxysmal AF keeps causing symptoms despite an antiarrhythmic medicine—or you cannot tolerate it—an electrophysiology assessment can help you choose between further medicine treatment and catheter ablation. Rhythm treatment and stroke prevention remain separate decisions.

Pulsed field ablation (PFA) uses electrical pulses instead of heat or freezing. It may limit damage to nearby tissues, but it has not been proved the best option for everyone. For AF episodes that stop within seven days, one large trial found similar one-year results—not a higher success rate with PFA.

Heart surgery options, specialist teams, published treatment prices and recovery evidence. Compare diagnoses, methods, doctors and clinics with source-linked facts.

Compare MR-guided focused ultrasound, staged bilateral treatment and DBS considerations, with source-checked programs, outcomes, risks and unanswered cost questions.

Treatment decision guide MESM after medication no longer controls obstructive HCM Compare the treatment paths first. A named programme, a smaller incision, or an invitation